Titan sees Braeburn as best partner to secure future of Probuphine
This article was originally published in Scrip
Titan Pharmaceuticals insists that multiple potential partners were interested in commercializing Probuphine (buprenorphine) in the US and Canada, but the company's executives said they signed a license deal with the startup firm Braeburn Pharmaceuticals to reduce the risk that the opioid addiction therapy delivered by a novel subdermal implant would be de-prioritized by a Big Pharma player.
You may also be interested in...
Private Company Edition: The Alliance for Regenerative Medicine’s half-year report shows the sector raised $10.7bn in the first half of 2020 versus $9.8bn raised in all of 2019. Also, DCVC Bio closed a $350m fund, new incubator opportunities and VC mega-deals for Dyne and Atomwise.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Expanding on difficult conversations during the recent BIO Digital meeting, the group aims to take actions that will increase diversity and inclusion in health care, science and industry.